InvestorsHub Logo
Followers 86
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: biopharm post# 211274

Saturday, 10/01/2016 9:26:27 AM

Saturday, October 01, 2016 9:26:27 AM

Post# of 345746
If BMS lose $25 Billion instantly for needing some other drug to increase responders....and BIIB Biogen increased $25 Billion with help of statistical significant reductions in amyloid levels, then there will be no need for a RS. Did Biogen open up or anything leak about a possible collaboration? Biogen is one that will be bought out unless they buy and/or merge with .....PS Targeting

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=111783994

"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News